NASDAQ · Financial Statements

Neurocrine Biosciences, Inc. (NBIX) Revenue, Earnings & Financial Statements

$162.86 NASDAQ: NBIX Market Cap $16.48B

Data as of Nov 18, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Neurocrine Biosciences, Inc. most recently reported annual revenue of $2.9B, net profit of $479.0M. Revenue grew at an average annual rate of 22.3% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Neurocrine Biosciences, Inc.: Revenue rose from $15.0M in 2016 to $2.9B in 2025, a change of +18973.3% over 9 years; net profit was positive in 8 of 10 reported years; operating margin moved from -982.5% to 21.6%, a shift of +1004.1 percentage points; the most recent year shows net profit of $479.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$15.0M$162.0M$451.0M$788.0M$1.0B$1.1B$1.5B$1.9B$2.4B$2.9B
Operating Expenses$162.0M$293.0M$414.0M$716.0M$883.0M$1.0B$1.2B$1.6B$1.8B$2.2B
Operating Profit−$147.0M−$131.0M$37.0M$72.0M$163.0M$103.0M$249.0M$251.0M$571.0M$619.0M
Operating Margin-982.5%-81.3%8.2%9.2%15.6%9.0%16.7%13.3%24.2%21.6%
Other Income$6.0M−$11.0M−$15.0M−$26.0M−$56.0M−$1.0M−$35.0M$81.0M−$84.0M$86.0M
Interest$0$20.0M$31.0M$32.0M$33.0M$26.0M$7.0M$5.0M$127.0M$0
Depreciation$1.0M$2.0M$4.0M$7.0M$9.0M$11.0M$16.0M$21.0M$27.0M$30.0M
Profit Before Tax−$141.0M−$143.0M$22.0M$47.0M$107.0M$101.0M$214.0M$332.0M$486.0M$705.0M
Tax rate (%)0.0%0.0%3.3%20.4%-281.7%11.6%27.8%24.8%29.8%32.1%
Net Profit−$141.0M−$143.0M$21.0M$37.0M$407.0M$90.0M$155.0M$250.0M$341.0M$479.0M
EPS−$1.63−$1.62$0.22$0.39$4.16$0.92$1.56$2.47$3.29$4.67

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$515.0M$515.0M$590.0M$622.0M$628.0M$573.0M$688.0M$795.0M$806.0M$815.0M$959.0M$1.1B
Operating Expenses$365.0M$416.0M$445.0M$438.0M$486.0M$549.0M$542.0M$556.0M$595.0M$629.0M$806.0M$791.0M
Operating Profit$150.0M$99.0M$145.0M$184.0M$142.0M$24.0M$146.0M$239.0M$211.0M$186.0M$153.0M$331.0M
Operating Margin29.2%19.3%24.6%29.6%22.6%4.1%21.2%30.1%26.2%22.8%15.9%29.5%
Interest$1.0M$1.0M$50.0M$0$0$0$0$0$0$0$3.0M$0
Profit Before Tax$198.0M$35.0M$99.0M$190.0M$163.0M$15.0M$160.0M$292.0M$239.0M$247.0M$162.0M$284.0M
Tax rate (%)25.5%-25.8%34.1%31.8%36.6%46.3%32.6%28.2%35.8%19.8%11.0%27.2%
Net Profit$148.0M$43.0M$65.0M$130.0M$103.0M$8.0M$108.0M$210.0M$154.0M$198.0M$144.0M$207.0M
EPS$1.44$0.42$0.63$1.24$1.00$0.08$1.06$2.04$1.48$1.91$1.39$1.96

Over the 10 years reported for Neurocrine Biosciences, Inc., cash stood at $713.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 3.40 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$365.0M$818.0M$993.0M$1.3B$1.7B$2.1B$2.4B$3.3B$3.7B$4.6B
Current Assets$310.0M$555.0M$738.0M$831.0M$1.0B$973.0M$1.5B$1.6B$1.7B$2.5B
Cash$83.0M$255.0M$142.0M$112.0M$187.0M$341.0M$263.0M$251.0M$233.0M$713.0M
Inventory$0$1.0M$11.0M$17.0M$28.0M$31.0M$35.0M$38.0M$57.0M$69.0M
Receivables$0$31.0M$57.0M$127.0M$157.0M$186.0M$350.0M$439.0M$479.0M$687.0M
Fixed Assets$6.0M$11.0M$34.0M$116.0M$127.0M$156.0M$146.0M$347.0M$592.0M$545.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$268.0M$509.0M$725.0M$914.0M$879.0M$995.0M$1.1B$1.6B$1.7B$2.0B
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$50.0M$445.0M$512.0M$669.0M$609.0M$699.0M$661.0M$1.0B$1.1B$1.4B
Current Liabilities$30.0M$54.0M$88.0M$565.0M$187.0M$246.0M$538.0M$655.0M$508.0M$743.0M
Borrowings$0$370.0M$388.0M$496.0M$412.0M$440.0M$263.0M$428.0M$455.0M$415.0M
Other Liabilities$50.0M$76.0M$124.0M$174.0M$196.0M$258.0M$398.0M$591.0M$674.0M$963.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$315.0M$372.0M$481.0M$637.0M$1.1B$1.4B$1.7B$2.2B$2.6B$3.3B

For Neurocrine Biosciences, Inc., operating cash flow was positive in 8 of 10 reported years; free cash flow in the latest year was $749.0M; free cash flow was positive in 8 of 10 years; financing activities used $168.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$106.0M−$94.0M$101.0M$147.0M$229.0M$257.0M$339.0M$390.0M$595.0M$783.0M
Investing Cash Flow$109.0M−$258.0M−$268.0M−$226.0M−$7.0M−$154.0M−$194.0M−$495.0M−$165.0M−$298.0M
Financing Cash Flow$0$0$0$5.0M$0$0$0$0−$300.0M−$168.0M
Net Cash Flow$9.0M$171.0M−$112.0M−$32.0M$75.0M$154.0M−$73.0M−$12.0M−$18.0M$480.0M
Free Cash Flow−$110.0M−$101.0M$77.0M$132.0M$218.0M$233.0M$323.0M$362.0M$557.0M$749.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.76
EV / EBITDA24.94
FCF Yield4.54%
Quick Ratio3.30
Interest Coverage275.38
Return 1Y15.51%
Return 3Y52.21%
Return 5Y89.49%

Neurocrine Biosciences, Inc. (NBIX) financials — frequently asked questions

What is Neurocrine Biosciences, Inc.'s annual revenue?

Neurocrine Biosciences, Inc. (NBIX) reported annual revenue of $2.9B in its most recent fiscal year.

What is Neurocrine Biosciences, Inc.'s net profit?

Neurocrine Biosciences, Inc. (NBIX) reported net profit of $479.0M in its most recent fiscal year.

What is NBIX EV/EBITDA?

Neurocrine Biosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 24.94.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
NBIX Overview NBIX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.